A股異動 | 凱萊英(002821.SZ)漲超6%破頂 市值超900億元
格隆匯5月17日丨凱萊英(002821.SZ)拉昇漲超6%,高見372元再創歷史新高價,總市值超900億元。該股自4月底以來加速上漲,累計漲幅高達25%持續刷新歷史高價。4月底凱萊英公佈,2021Q1季度實現營業收入7.77億元,同比增長63.45%;歸母淨利潤1.54億元,同比增長42.86%。績後獲券商扎堆唱好。浙商證券指出,訂單產能共振,業績加速確定,維持“買入”評級;海通證券表示,充分的產能+充沛的訂單保障業績持續高增長,認為業績仍然具有較大的上升空間;西南證券認為公司業績增長符合預期,2021值得期待。此外,日前公司榮獲中國上市公司最佳投資者關係獎。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.